Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
431 stopped studies mapped to Urinary System Carcinoma and descendants · 87% state a reason
Over the 431 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01943188 | Stereotactic Body Radiation Therapy and T-Cell Infusion in Treating Patients With… | Phase 1 | terminated | Sep 16, 2013 | Stanford University | not stated | Not stated |
| NCT01441765 | PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine | Phase 2 | terminated | Sep 28, 2011 | Beth Israel Deaconess Medical Center | Funding | Funding |
| NCT02273752 | Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic… | Phase 2 | terminated | Oct 24, 2014 | Emory University | Slow accrual | Enrollment / accrual |
| NCT00672178 | Stereotactic Body Radiotherapy (SBRT) and Sorafenib in Patients With Metastatic,… | Phase 1 / Phase 2 | terminated | May 6, 2008 | Duke University | Slow accrual | Enrollment / accrual |
| NCT01712685 | Imaging Studies of Kidney Cancer Using 18F-VM4-037 | Phase 2 | terminated | Oct 23, 2012 | National Cancer Institute (NCI) | Study was closed to accrual because imaging agent was no longer available. | Enrollment / accrual |
| NCT02410174 | To Evaluate Stereotactic Body Radiotherapy for Treatment of Primary Renal Cell Carcinoma… | Phase 1 | terminated | Apr 7, 2015 | Beth Israel Medical Center | Poor Accural | Other (stated, no rule matched) |
| NCT00565227 | Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and… | Phase 1 | terminated | Nov 29, 2007 | University of Michigan Rogel Cancer Center | closed due to toxicity | Safety / toxicity |
| NCT01144169 | Study of Hydroxychloroquine Before Surgery in Patients With Primary Renal Cell Carcinoma | Phase 1 | terminated | Jun 15, 2010 | University of Pittsburgh | barriers to accrual: delay until surgery and additional pre-operative visits | Enrollment / accrual |
| NCT00061178 | Efficacy and Safety Study of rhuMAb VEGF to Treat Metastatic Renal Cell Carcinoma | Phase 3 | withdrawn | May 23, 2003 | Genentech, Inc. | No patients were enrolled, study cancelled before start | Enrollment / accrual |
| NCT01829971 | A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection | Phase 1 | terminated | Apr 11, 2013 | Mirna Therapeutics, Inc. | Five immune related serious adverse events | Safety / toxicity |
| NCT00318110 | Matched Unrelated Donor Transplant for Metastatic Renal Cell Carcinoma | Phase 2 | terminated | Apr 26, 2006 | Center for International Blood and Marrow Transplant Research | Unable to meet subject enrollment goal. | Enrollment / accrual |
| NCT01326390 | Impact of C-arm CT in Decreased Renal Function Undergoing TACE for Tx of Hepato-Cellular… | — | terminated | Mar 30, 2011 | Stanford University | not stated | Not stated |
| NCT02718742 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy… | Phase 2 | withdrawn | Mar 24, 2016 | Mayo Clinic | not stated | Not stated |
| NCT02479178 | A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical…(iNSITE2) | Phase 2 | terminated | Jun 24, 2015 | BIND Therapeutics | not stated | Not stated |
| NCT00556205 | Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell Carcinoma | Phase 2 | withdrawn | Nov 9, 2007 | Massachusetts General Hospital | Toxicity of combination from other trials | Safety / toxicity |
| NCT00440973 | Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With… | Phase 2 | terminated | Feb 27, 2007 | The Methodist Hospital Research Institute | contract issues | Other (stated, no rule matched) |
| NCT00522249 | Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC | Phase 1 / Phase 2 | terminated | Aug 29, 2007 | The Methodist Hospital Research Institute | PI decision | Other (stated, no rule matched) |
| NCT02307474 | A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer | N/A | withdrawn | Dec 4, 2014 | Case Comprehensive Cancer Center | Funding Unavailable | Funding |
| NCT01762033 | A Phase 2 Study of ASONEP™ to Treat Unresectable and Refractory Renal Cell Carcinoma | Phase 2 | terminated | Jan 7, 2013 | Lpath, Inc. | not stated | Not stated |
| NCT01771003 | Remote Ischemia Pre-Conditioning in Patients Undergoing Partial Nephrectomy | N/A | terminated | Jan 18, 2013 | University Health Network, Toronto | not stated | Not stated |
| NCT00480935 | A Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma | Phase 2 | terminated | May 31, 2007 | University Health Network, Toronto | poor recruitment | Enrollment / accrual |
| NCT00913913 | Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell… | Phase 2 | terminated | Jun 4, 2009 | Dartmouth-Hitchcock Medical Center | low accrual not allowing site to meeting statistical endpoints | Enrollment / accrual |
| NCT01977586 | Functional Imaging in the Assessment of mRCC Response to Sunitinib | N/A | withdrawn | Nov 6, 2013 | Imperial College Healthcare NHS Trust | Difficulty in recruiting suitable patients at centre | Enrollment / accrual |
| NCT01342627 | Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma(SERCC) | Phase 2 | terminated | Apr 27, 2011 | Centro di Riferimento Oncologico - Aviano | low enrollment rate | Enrollment / accrual |
| NCT01100242 | Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma | Phase 2 | terminated | Apr 8, 2010 | New Mexico Cancer Research Alliance | Low accrual | Enrollment / accrual |
| NCT01071928 | Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma | Phase 2 | withdrawn | Feb 19, 2010 | Hoosier Cancer Research Network | Lack of efficacy of experimental treatment | Efficacy / futility |
| NCT00574483 | Treatment of Advanced Renal Cell Carcinoma With Quinacrine | Phase 2 | withdrawn | Dec 17, 2007 | Cleveland BioLabs | reevaluation of compound development | Other (stated, no rule matched) |
| NCT00176280 | Randomized Phase 2 Trial of Pre-chemotherapy Leukine vs. Leukine-Dexamethasone in… | Phase 2 | withdrawn | Sep 15, 2005 | University of Kentucky | Slow accrual | Enrollment / accrual |
| NCT01507740 | Profile of Soluble and Cellular Biomarkers and of Functional Imaging During… | — | terminated | Jan 11, 2012 | Medical University Innsbruck | Study was stopped 04.10.2014 prematurly after recruitment of HCC and RCC patients. NSCLC (2 of 10… | Enrollment / accrual |
| NCT00930345 | Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic…(PREINSUT) | Phase 4 | terminated | Jun 30, 2009 | Assistance Publique - Hôpitaux de Paris | not stated | Not stated |
| NCT01547676 | Clamped or Unclamped Surgery in Treating Patients With Kidney Cancer | N/A | terminated | Mar 8, 2012 | University of Southern California | P.I. decided to terminate study due to multiple unresolved issues | Other (stated, no rule matched) |
| NCT01720693 | Novel Controlled Hypo-Perfusion Technique in Partial Nephrectomy | Phase 2 | terminated | Nov 2, 2012 | University Health Network, Toronto | Low accrual | Enrollment / accrual |
| NCT01353794 | Study to Observe Safety and Efficacy of Nexavar in Treatment of Kidney Cancer(POWER-NEXT) | — | withdrawn | May 16, 2011 | Bayer | not stated | Not stated |
| NCT00352859 | Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib | Phase 4 | terminated | Jul 17, 2006 | Bayer | not stated | Not stated |
| NCT00072137 | Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who… | Phase 1 | terminated | Nov 6, 2003 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00622479 | Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia. | Phase 1 | terminated | Feb 25, 2008 | Bayer | not stated | Not stated |
| NCT00678288 | A Study to Assess Sorafenib Alone and in Combination With Low-Dose Interferon Following… | Phase 2 | terminated | May 15, 2008 | Bayer | not stated | Not stated |
| NCT00001703 | Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With… | Phase 2 | terminated | Nov 4, 1999 | National Cancer Institute (NCI) | Due to poor accrual and lack of peptide vaccine | Enrollment / accrual |
| NCT01793636 | A Study Comparing AZD2014 vs Everolimus in Patients With Metastatic Renal Cancer(ZEBRA) | Phase 2 | terminated | Feb 15, 2013 | Queen Mary University of London | Inferior efficacy of study drug in renal indication. | Efficacy / futility |
| NCT00112905 | Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium | Phase 2 | terminated | Jun 3, 2005 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00303862 | AZD2171 in Treating Patients With Refractory Metastatic Kidney Cancer | Phase 2 | terminated | Mar 17, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00684996 | Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic… | Phase 1 / Phase 2 | terminated | May 28, 2008 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01907308 | Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma | Phase 2 | withdrawn | Jul 24, 2013 | University of Colorado, Denver | Sponsor's decision to terminate the study | Sponsor / business decision |
| NCT00523640 | A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell… | Phase 2 | terminated | Aug 31, 2007 | University of Chicago | Too slow accrual | Enrollment / accrual |
| NCT00942058 | Serum CA9 Level as Biological Marker of the Treatment Response in Metastatic Renal Cell…(CA9CRM) | — | terminated | Jul 20, 2009 | Centre Hospitalier Universitaire de Saint Etienne | Difficult for recruiting | Enrollment / accrual |
| NCT01677390 | A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell… | Phase 1 | terminated | Sep 3, 2012 | Seagen Inc. | not stated | Not stated |
| NCT01063998 | A Urinary Tumor Marker (Kidney Injury Molecule-1) for the Detection of Renal Cell… | — | terminated | Feb 5, 2010 | Jason Hafron | Preliminary data did not show expected outcomes. | Other (stated, no rule matched) |
| NCT00110344 | Research Study for Patients With Metastatic Renal Cell Carcinoma | Phase 2 | terminated | May 9, 2005 | Bayer | not stated | Not stated |
| NCT00203866 | Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally… | Phase 2 | terminated | Sep 20, 2005 | University of Chicago | Study completed | Other (stated, no rule matched) |
| NCT00557830 | Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated… | Phase 2 | terminated | Nov 14, 2007 | Accelerated Community Oncology Research Network | The study was closed to enrollment when it became clear that enrollment was too slow to complete… | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Mar 15, 2017source: clinicaltrials